BioElectronics receives product approvals
This article was originally published in The Tan Sheet
Executive Summary
Health Canada approves BioElectronics Corp.'s Allay Menstrual Pain Therapy product for OTC sale to treat menstrual pain symptoms. The Frederick, Md.-based company also announces June 29 that South Korea's regulators approved its ActiPatch for reducing muscle pain. "With its proven technology and established clinical platform, Allay and ActiPatch are very unique brands in both Canada and Korea," the company said. BioElectronics noted the approvals open doors into new markets. The firm's pain relief products already are available in 44 countries worldwide
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.